MX2021014102A - Terapia de vacuna anti-abeta. - Google Patents
Terapia de vacuna anti-abeta.Info
- Publication number
- MX2021014102A MX2021014102A MX2021014102A MX2021014102A MX2021014102A MX 2021014102 A MX2021014102 A MX 2021014102A MX 2021014102 A MX2021014102 A MX 2021014102A MX 2021014102 A MX2021014102 A MX 2021014102A MX 2021014102 A MX2021014102 A MX 2021014102A
- Authority
- MX
- Mexico
- Prior art keywords
- âμg
- administered
- mpla
- amyloid
- inducing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Una composición de vacuna liposomal que comprende: a. un antígeno peptídico derivado de ß-amiloide (Aß) que se muestra en la superficie del liposoma que comprende, consiste esencialmente en o consiste en los aminoácidos 1-15 de Aß b. un adyuvante que comprende monofosforil lípido A (MPLA) es usado para inducir una respuesta inmune anti-Aß en un sujeto humano sin inducir un evento adverso grave. El antígeno peptídico derivado de ß-amiloide (Aß) (SEQ ID No: 1) es administrado en una cantidad de 300-2000 µg, preferentemente alrededor de 1000 µg. El MPLA es administrado en una cantidad de 15-600 µg, preferentemente alrededor de 175 µg. La composición de vacuna liposomal es administrada por vía intramuscular o subcutánea.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175810 | 2019-05-21 | ||
| EP19185593 | 2019-07-10 | ||
| EP20171549 | 2020-04-27 | ||
| EP20172205 | 2020-04-29 | ||
| PCT/EP2020/064172 WO2020234405A1 (en) | 2019-05-21 | 2020-05-20 | Anti-abeta vaccine therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014102A true MX2021014102A (es) | 2022-02-11 |
Family
ID=70740677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014102A MX2021014102A (es) | 2019-05-21 | 2020-05-20 | Terapia de vacuna anti-abeta. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220226447A1 (es) |
| EP (1) | EP3972633A1 (es) |
| JP (1) | JP2022533422A (es) |
| KR (1) | KR20220010552A (es) |
| CN (1) | CN113853214A (es) |
| AU (1) | AU2020277682A1 (es) |
| BR (1) | BR112021023209A2 (es) |
| CA (1) | CA3138145A1 (es) |
| CL (1) | CL2021003051A1 (es) |
| IL (1) | IL288252A (es) |
| MX (1) | MX2021014102A (es) |
| SG (1) | SG11202112329RA (es) |
| TW (1) | TW202110425A (es) |
| WO (1) | WO2020234405A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024156912A1 (en) * | 2023-01-26 | 2024-08-02 | Ac Immune Sa | Anti-abeta vaccine therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| KR101236611B1 (ko) | 2005-12-12 | 2013-03-04 | 에이씨 이뮨 에스.에이. | 치료 백신 |
| WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
| CN103189050B (zh) | 2010-10-26 | 2017-09-29 | Ac免疫有限公司 | 包含通过疏水部分修饰的肽的基于脂质体的构建体 |
| CA2811188C (en) | 2011-09-23 | 2020-04-28 | Andrea Pfeifer | Vaccine therapy |
-
2020
- 2020-05-20 SG SG11202112329RA patent/SG11202112329RA/en unknown
- 2020-05-20 KR KR1020217041697A patent/KR20220010552A/ko unknown
- 2020-05-20 JP JP2021569155A patent/JP2022533422A/ja active Pending
- 2020-05-20 US US17/612,921 patent/US20220226447A1/en active Pending
- 2020-05-20 TW TW109116790A patent/TW202110425A/zh unknown
- 2020-05-20 EP EP20726473.0A patent/EP3972633A1/en active Pending
- 2020-05-20 CA CA3138145A patent/CA3138145A1/en active Pending
- 2020-05-20 AU AU2020277682A patent/AU2020277682A1/en active Pending
- 2020-05-20 WO PCT/EP2020/064172 patent/WO2020234405A1/en active Application Filing
- 2020-05-20 MX MX2021014102A patent/MX2021014102A/es unknown
- 2020-05-20 CN CN202080035690.8A patent/CN113853214A/zh active Pending
- 2020-05-20 BR BR112021023209A patent/BR112021023209A2/pt unknown
-
2021
- 2021-11-18 CL CL2021003051A patent/CL2021003051A1/es unknown
- 2021-11-21 IL IL288252A patent/IL288252A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3138145A1 (en) | 2020-11-26 |
| SG11202112329RA (en) | 2021-12-30 |
| CN113853214A (zh) | 2021-12-28 |
| US20220226447A1 (en) | 2022-07-21 |
| IL288252A (en) | 2022-01-01 |
| WO2020234405A1 (en) | 2020-11-26 |
| JP2022533422A (ja) | 2022-07-22 |
| AU2020277682A1 (en) | 2021-12-23 |
| KR20220010552A (ko) | 2022-01-25 |
| CL2021003051A1 (es) | 2022-07-22 |
| BR112021023209A2 (pt) | 2022-01-18 |
| TW202110425A (zh) | 2021-03-16 |
| EP3972633A1 (en) | 2022-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barr et al. | ISCOMs (immunostimulating complexes): the first decade | |
| HRP20181102T1 (hr) | Cjepiva za hsv-2 | |
| ES2886999T3 (es) | Procedimiento para mejorar la eficacia de una vacuna de survivina en el tratamiento de cáncer | |
| CA2181832A1 (en) | Immunization by inoculation of dna transcription unit | |
| BR9509190A (pt) | Composição de vacina produto farmacêutico processos para imunizar um portador contra infecção gripal para aperfeiçoar uma resposta imune de mucosa de iga protetora e uma resposta imune sistêmica e igg e para aperfeiçoar a resposta imune de antigenos de vírus de gripe e uso de um quitosano | |
| US20050002951A1 (en) | Novel method of inducing antigen-specific t cells | |
| EE200200507A (et) | Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine | |
| AU2012257771B2 (en) | Vaccine against Streptococcus pneumoniae | |
| WO2005000348A2 (en) | Vaccines inducing nkt-cell and toll-like-receptor activation | |
| JP2018500322A5 (es) | ||
| JP2017501172A5 (es) | ||
| Decker et al. | Cytokine adjuvants for vaccine therapy of neoplastic and infectious disease | |
| JOP20210211A1 (ar) | طريقة إعطاء دواء آمنة للقاح ببتيد تاو المفسفر | |
| JP6655549B2 (ja) | 免疫応答を誘導するための新規方法 | |
| JOP20210284A1 (ar) | الإعطاء غير المتجانس للقاحات تاو | |
| JP2017511327A5 (es) | ||
| MX2021014102A (es) | Terapia de vacuna anti-abeta. | |
| DK2491946T3 (en) | Adjuvant for vaccines | |
| Arakelian et al. | Pyroptosis-inducing active caspase-1 as a genetic adjuvant in anti-cancer DNA vaccination | |
| PH12020551670A1 (en) | Anti-abeta therapeutic vaccines | |
| WO2017070735A1 (en) | Liposomal vaccine | |
| CA2372181A1 (en) | Adjuvant combination formulations | |
| US11497805B2 (en) | Toll-like receptor 2 agonists and vaccines and uses thereof | |
| EA202193183A1 (ru) | Терапия с помощью вакцины против бета-амилоида | |
| WO2013171661A3 (en) | Adjuvant formulations and methods |